In the event that Selecta reasonably demonstrates that Spark’s Development activities under this ARTICLE 3 (Development) could reasonably be expected to negatively impact Selecta’s or any of its Affiliates’ or licensees’ Development or Commercialization of other products containing a Licensed Particle (a “ Licensed Particle Dispute ”), then Selecta may refer the matter to the Project Coordinators who shall thereafter negotiate in good faith to resolve the Licensed Particle Dispute and, if appropriate, recommend amendments to the Development Plan to address Selecta’s concerns. If the Project Coordinators cannot resolve the Licensed Particle Dispute within [**], the Licensed Particle Dispute shall be discussed in good faith by the Chief Executive Officers of Spark and Selecta (or an appropriate senior executive designated by such Chief Executive Officer), provided that (i) a Licensed Particle Dispute that is not resolved by the Chief Executive Officers (or an appropriate senior executive designated by such Chief Executive Officer) within [**], other than a Licensed Particle Dispute related to patient safety with respect to a proposed or ongoing Clinical Trial, shall be finally resolved by the Chief Executive Officer of Spark (or an appropriate senior executive designated by such Chief Executive Officer) and (ii) a Licensed Particle Dispute related to patient safety with respect to a proposed or ongoing Clinical Trial that is not resolved by the Chief Executive Officers (or appropriate senior executives designated by such Chief Executive Officers) within [**] shall be referred to the data safety monitoring board constituted by Spark for such proposed Clinical Trial (“ DSMB ”) or, if such DSMB has not been constituted at the time of the Licensed Particle Dispute, to Spark’s Scientific Advisory Board (“ SAB ”) for resolution in accordance with Section 3.7(b) (Data Safety Monitoring Board).